Achieve Life Sciences Inc. (ACHV)

3.45 -0.095 (-2.68%)

IEX Real-Time Price

July 16, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 3.545

Price Open 3.53

Volume: 264,312

Avg Volume: 1.92M

Market Cap: 9.54M

P/E Ratio -

52 Wk Range 3.28-52.8



ACHV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-06-15
2.76M
77,912
0.91
2.82%

2018-05-31
129,079
45,443
0.70
35.21%

2018-05-15
129,079
51,553
0.89
39.94%

2018-04-30
10.15M
556,139
12.50
5.48%




ACHV Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-01
Q4 2017
N/A
0.00 (0)
-0.32
0.00

2018-02-22
Q4 2017
N/A
0.00 (0)
-0.32
0.00

2017-02-23
Q4 2016
N/A
0.00 (0)
-0.32
0.00

News

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters (2018-07-13 04:16 SeekingAlpha)

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti…

 


Statistics

Shares Outstanding: 2.76M

Top 15 Institution Percent: 5.30

Price To Sales: N/A

Price To Book: 1.60

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -76.86

Return On Equity: -91.96

Profit Margin: N/A

Price History

Beta: 1.96

50-day Moving Avg: 7.81

200-day Moving Avg: 13.27

YTD Change: -75.38

5-day Change: -3.67

1-month Change: 0.71

3-month Change: -73.14

6-month Change: -76.37

1-year Change: -92.89

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Achieve Life Sciences Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.achievelifesciences.com

Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next generation cancer therapeutics.